Roivant & Immunovant (ROIV & IMVT): Unlocking the Potential of Targeted Immunology

What if one biological mechanism could create new treatment opportunities across several autoimmune diseases?

That question is central to the work underway at Roivant Sciences (ROIV) and its majority-owned subsidiary, Immunovant (IMVT).

The companies recently announced encouraging results for IMVT-1402, an investigational antibody therapy targeting the neonatal Fc receptor, or FcRn.

Why does FcRn matter?

Our immune systems produce antibodies to protect us from disease. But in certain autoimmune conditions, antibodies mistakenly attack healthy tissues.

FcRn helps recycle immunoglobulin G (IgG) antibodies, extending their time in circulation.

By blocking FcRn, IMVT-1402 is designed to reduce circulating IgG, including antibodies that may contribute to autoimmune disease.

This approach could have applications across multiple conditions that share an underlying antibody-driven disease mechanism.

The latest clinical results are particularly interesting.

On November 9, 2026, Immunovant reported positive results from a randomized-withdrawal study in patients with difficult-to-treat rheumatoid arthritis.

These were patients with substantial prior treatment exposure, including many who had failed multiple advanced therapies.

After an initial 16-week treatment period, patients who responded were randomized to continue IMVT-1402 or receive a lower dose or placebo.

At Week 28:

• 92.5% of patients continuing the 600 mg dose maintained an ACR20 response, compared with 75.6% receiving placebo.

• 80.0% achieved an ACR50 response, compared with 56.1% receiving placebo.

• 52.5% achieved an ACR70 response, compared with 36.6% receiving placebo.

The primary ACR20 endpoint was statistically significant. ACR50 was supportive in an exploratory analysis, while the ACR70 difference did not reach statistical significance.

These results are noteworthy because they suggest that sustained FcRn inhibition may help maintain clinical responses in a challenging rheumatoid arthritis population.

Why the rheumatoid arthritis results matter

The study enrolled patients with particularly challenging disease histories. In the randomized-withdrawal population, approximately 99% had previously failed at least two advanced treatment mechanisms.

But rheumatoid arthritis is only one part of the opportunity.

Endpoint	600 mg vs. placebo	Statistical result
ACR20 maintenance	92.5% vs. 75.6%	p = 0.0139
ACR50 maintenance	80.0% vs. 56.1%	p = 0.0117
ACR70 maintenance	52.5% vs. 36.6%	p = 0.1674

The distinction is important: ACR20 and ACR50 met conventional statistical significance thresholds; ACR70 did not. The study also selected initial responders before randomization, so these percentages should not be interpreted as response rates for all patients starting IMVT-1402.

The 300 mg arm did not achieve statistical significance on ACR20 versus placebo, suggesting that dose and depth of IgG reduction may be important. However, the study does not by itself prove that deeper IgG lowering will produce better outcomes across every autoimmune disease.

Immunovant is also advancing IMVT-1402 in Graves' disease and myasthenia gravis, with potentially registrational clinical results expected in 2027.

Additional data in chronic inflammatory demyelinating polyneuropathy are expected in 2028.

These programs offer several opportunities to test the same therapeutic mechanism across distinct autoimmune diseases.

Roivant's broader portfolio adds another dimension.

In August 2026, Roivant's affiliate Priovant received FDA approval for LISRAYA (brepocitinib) in adults with dermatomyositis.

The treatment generated $31 million in net product revenue during its first five weeks of commercialization.

Brepocitinib also recently demonstrated positive results in two Phase 3 studies of non-infectious uveitis, supporting plans for an additional regulatory submission.

Roivant's November 9 update provides three additional developments that make the combined story especially interesting:

Program	Latest development	Investment relevance
IMVT-1402	Positive randomized-withdrawal RA data	Potential expansion of FcRn inhibition
LISRAYA (brepocitinib)	$31M in net sales during first five weeks after approval for adult dermatomyositis	Early evidence of commercialization
Brepocitinib in uveitis	Two positive Phase 3 trials	Potential additional indication, subject to FDA review

Roivant also reported approximately $4.2 billion in consolidated cash, equivalents and marketable securities at September 30, 2026. This includes cash within consolidated subsidiaries, so it should not be interpreted as unrestricted cash available solely to Roivant's parent company

Why this matters for healthcare investors

The opportunity in biotechnology is not always limited to a single drug or disease.

A well-understood biological mechanism may create the foundation for several potential treatments, each with its own clinical evidence, regulatory requirements and commercial opportunity.

At the same time, the risks remain substantial. IMVT-1402 is investigational, future trials must confirm its benefits, and the competitive landscape in autoimmune disease continues to evolve.

Upcoming milestones

Timing	Program	What to watch
Late 2026	IMVT-1402 in difficult-to-treat RA	FDA discussions regarding registrational development
2027	IMVT-1402 in Graves' disease	Potentially registrational topline results
2027	IMVT-1402 in myasthenia gravis	Potentially registrational topline results
H1 2027	Brepocitinib in non-infectious uveitis	Planned supplemental FDA submission
2028	IMVT-1402 in CIDP	Potentially registrational topline results

These are company-anticipated milestones, not guaranteed outcomes. Immunovant has also indicated that it is unlikely to advance its Sjögren's disease program beyond the ongoing Phase 2 trial—a reminder that portfolio development involves prioritization and setbacks as well as successes.